Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Merck
Colorcon
AstraZeneca
Moodys

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

PERJETA Drug Profile

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for PERJETA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
AstraZenecaPhase 2
Renske AltenaPhase 2
PfizerPhase 2

See all PERJETA clinical trials

Recent Litigation for PERJETA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
Genentech, Inc. v. Amgen Inc.2018-06-21
Celltrion, Inc. v. Genentech, Inc.2018-01-11

See all PERJETA litigation

Pharmacology for PERJETA
Mechanism of ActionHER2/Neu/cerbB2 Antagonists

Patent Text Search: US Patents for PERJETA

These patents were identified by searching patent claims

Supplementary Protection Certificates for PERJETA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1590004-6 Sweden   Start Trial PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808
CA 2015 00006 Denmark   Start Trial PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805
122015000013 Germany   Start Trial PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE (IMNOVID); REGISTRATION NO/DATE: EU/1/13/850 20130805
212 50002-2015 Slovakia   Start Trial PRODUCT NAME: POMALIDOMID; REGISTRATION NO/DATE: EU/1/13/850/001 - EU/1/13/850/004 20130808
C300717 Netherlands   Start Trial PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
300717 Netherlands   Start Trial PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805
00140 Estonia   Start Trial
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKesson
Moodys
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.